Stephen P. Mulligan

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · The Lancet Oncology · 2016 · 796 citations · Full text

Medicine, Hematology, Immunology +7

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Talha Munir, Jennifer R. Brown, Susan O’Brien et al. · American Journal of Hematology · 2019 · 473 citations · Full text

Medicine, Oncology, Pharmacology +14

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.

Larissa Belov, O de la Vega, Cristobal G. dos Remedios et al. · PubMed · 2001 · 318 citations

Medicine, Hematology, Oncology +15